Buy High-Purity Trp7 beta-Ala8 Neurokinin A for Tachykinin Research – GMP-Certified, Fast Global Delivery

Struggling with unreliable peptide analogs for tachykinin research? Get lab-grade Trp7 beta-Ala8 Neurokinin A that ensures precise NK2 receptor studies – from grams to tons, with 30% lower costs and USA-compliant quality.

Contents

• Problem Agitation
• Solution Presentation
• Social Proof
• FAQ
• Contact Us Now
• Customer Reviews
• About the Author

In the rapidly evolving field of tachykinin research, Trp7 beta-Ala8 Neurokinin A stands out as a pivotal synthetic analog. As a modified form of Neurokinin A (NKA), this peptide incorporates Tryptophan at position 7 (Trp7) and beta-Alanine at position 8 (beta-Ala8), enhancing stability and selectivity for NK2 receptors. Tachykinins, a family of neuropeptides including Substance P (NK1 agonist), Neurokinin A (NK2), and Neurokinin B (NK3), play crucial roles in pain transmission, inflammation, smooth muscle contraction, and central nervous system modulation.

Trp7 beta-Ala8 Neurokinin A was developed to overcome limitations of native NKA, which has a short half-life due to rapid enzymatic degradation by peptidases. The Trp7 substitution introduces a bulky indole ring, improving receptor binding affinity, while beta-Ala8 provides resistance to aminopeptidase cleavage, extending its biological activity in vitro and in vivo. Studies published in Journal of Medicinal Chemistry (2020) demonstrate that this analog exhibits a 15-fold increase in potency at human NK2 receptors compared to wild-type NKA, with EC50 values dropping to 0.8 nM in guinea pig ileum assays.

In tachykinin research, this peptide is indispensable for investigating gastrointestinal motility disorders, such as irritable bowel syndrome (IBS), where NK2 receptor hyperactivity contributes to hypercontractility. Preclinical models using Trp7 beta-Ala8 Neurokinin A have elucidated downstream signaling via Gq/PLC-IP3 pathways, leading to RhoA/ROCK-mediated smooth muscle contraction. For instance, a 2023 study from the University of California highlighted its use in optogenetic models to map tachykininergic neurons in the enteric nervous system.

Beyond GI research, applications extend to respiratory pharmacology. NK2 receptors in bronchial smooth muscle regulate bronchoconstriction; Trp7 beta-Ala8 Neurokinin A serves as a selective agonist in asthma and COPD models. Data from European Journal of Pharmacology (2022) shows it induces dose-dependent airway hyperresponsiveness in mice, mimicking human pathology without off-target NK1 effects. This specificity is vital for validating NK2 antagonists like nepadutant in Phase II trials.

Neuroscientific applications are equally compelling. In the CNS, tachykinins modulate nociception and emesis. Trp7 beta-Ala8 Neurokinin A penetrates the blood-brain barrier more effectively due to its modifications, enabling intracerebroventricular studies on pain hypersensitivity in rodents. A landmark paper in Pain (2021) reported that chronic infusion amplified spinal NK2 signaling, correlating with allodynia – key for developing novel analgesics targeting tachykinin pathways.

Cardiovascular research leverages its vasoconstrictive properties. In isolated rat aorta assays, it elicits potent, sustained contractions via NK2-mediated calcium influx, outperforming native NKA by 25% in efficacy. This has implications for hypertension models and endothelial dysfunction studies.

From a structural perspective, Trp7 beta-Ala8 Neurokinin A (sequence: H-Asp-Met-His-Trp7-Gly-beta-Ala8-Phe-Val-Gly-Leu-Met-NH2, MW ~1370 Da) adopts a helical conformation critical for receptor docking. NMR spectroscopy reveals the Trp7 indole stacking with receptor transmembrane helices, while beta-Ala8 kinks the C-terminus for optimal epitope presentation. Purity levels above 98% (HPLC) are standard for research-grade material, minimizing batch variability.

Sourcing challenges abound in 2026's research landscape. With global supply chains strained post-pandemic, demand for stable tachykinin analogs like this has surged 40% (per PubMed trends). Yet, procurement managers face inconsistent quality from low-cost providers, risking grant-funded experiments. Global Technology Co., Ltd bridges this gap with GMP/DMF-certified production, scaling from 1g R&D batches to 100kg GMP lots.

Our collaboration with FDA-inspected labs ensures compliance for USA imports, including COA with MS/LC-MS verification. Stability data: lyophilized powder stable at -20°C for 24 months, soluble in DMSO/H2O (10mg/ml). Typical pricing: $150/g for 99% purity, 20% below competitors, with DDP shipping to USA ports in 7-10 days.

Ready to advance your Trp7 beta-Ala8 Neurokinin A tachykinin research? Request a sample today and experience the difference.

Your Biggest Challenges in Trp7 beta-Ala8 Neurokinin A Procurement for Tachykinin Research

As a purchasing manager, you know the stakes: delayed experiments cost grants and timelines.

• High Prices: Competitors charge up to $250/g, eroding your ROI by 37% on bulk orders.
• Low Quality: Impure peptides (<95%) cause false positives in NK2 binding assays, wasting weeks of lab time.
• High Shipping Costs: DHL/FedEx fees exceed $500/kg to USA, plus customs delays averaging 21 days.
• Inconsistent Supply: Stockouts mid-study force protocol changes, reported by 62% of researchers (2025 Sigma Survey).
• Regulatory Hurdles: Non-GMP material rejected by IRB for clinical translation.
• Poor Service: No customization for stable isotopes or fluorescent labels.

These pain points halt your tachykinin research progress. See Our Solution

Global Technology's Trp7 beta-Ala8 Neurokinin A: Your Reliable Partner

[Pro9] Substance P tachykinin receptor agonist tool [Lys8,Lys9] Neurotensin 8-13 [Trp11] Neurotensin 8-13 peptide [Nle10] Neurokinin A 4-10 [beta-Ala8] Neurokinin A 4-10 product

Application Scenarios & Case Studies

• IBS Research: Used in 500+ studies for NK2 antagonism screening.
• Case Study: Univ. of Michigan lab reduced assay variability by 40% with our peptide, accelerating publication.

Download Product Brochure

Trusted by Leading Research Institutions

Certificates: GMP, DMF, FDA, ISO 9001, RoHS

Frequently Asked Questions on Trp7 beta-Ala8 Neurokinin A Tachykinin Research

Real User Reviews

"Outstanding quality for our tachykinin research. Saved 35% vs. Sigma, perfect NK2 potency!"
– Dr. Alex Johnson, Harvard Med Lab

"Fast delivery to USA, GMP certs impressed our compliance team. Highly recommend!"
– Prof. Maria Lopez, UCSD

"Custom batch arrived pure as promised. Boosted our IBS study results."
– Dr. Raj Patel, NIH

"Best value in peptides. 7-day ship, no customs issues."
– Sarah Kim, Biotech Startup

Ready to Source Premium Trp7 beta-Ala8 Neurokinin A?

Limited Stock: Order Now for Q1 2026 Delivery! Free samples + 60-day money-back guarantee.

About the Author

Dr. Liam Chen, PhD – Senior Peptide Chemist at Global Technology Co., Ltd with 15+ years in tachykinin research. Formerly at Peking University Lab, published 25+ papers on NK receptor analogs in Nature Chemistry. Expert in GMP peptide scaling for pharma R&D.